Score Overview
Explore the 2021 public Archive ranking →
Where United Therapeutics Corporation has ranked, year by year
Showing 1 year ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- UTHR
2004: 31.2% · 2021: 4.6% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-30 | $ 541.89 | — |
1 Year2025-09-30 | $ 419.21 | 29.26% |
5 Years2021-09-30 | $ 184.58 | 193.58% |
10 Years2016-09-30 | $ 118.08 | 358.92% |
20 Years2006-09-29 | $ 26.31 | 20x |
All Time1999-06-17 | $ 6.09 | 88x |
| Period | Last Price2026-09-30 | 1 Year2025-09-30 | 5 Years2021-09-30 | 10 Years2016-09-30 | 20 Years2006-09-29 | All Time1999-06-17 |
|---|---|---|---|---|---|---|
| Price | $ 541.89 | $ 419.21 | $ 184.58 | $ 118.08 | $ 26.31 | $ 6.09 |
| Return | — | 29.26% | 193.58% | 358.92% | 20x | 88x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 3.15B | $ 1.31B | $ 2.66B |
| 2025 | $ 3.18B | $ 1.33B | $ 1.55B |
| 2024 | $ 2.87B | $ 1.19B | $ 3.26B |
| 2023 | $ 2.32B | $ 984M | $ 2.99B |
| 2022 | $ 1.93B | $ 727M | $ 2.83B |
| 2021 | $ 1.68B | $ 475M | $ 1.93B |
| 2020 | $ 1.48B | $ 514M | $ 1.83B |
| 2019 | $ 1.44B | -$ 104M | $ 1.48B |
| 2018 | $ 1.62B | $ 589M | $ 1.41B |
| 2017 | $ 1.72B | $ 417M | $ 1.43B |
| 2016 | $ 1.59B | $ 713M | $ 1.05B |
| 2015 | $ 1.46B | $ 651M | $ 953M |
| 2014 | $ 1.28B | $ 340M | $ 695M |
| 2013 | $ 1.11B | $ 174M | $ 693M |
| 2012 | $ 916M | $ 304M | $ 479M |
| 2011 | $ 743M | $ 217M | $ 403M |
| 2010 | $ 603M | $ 105M | $ 627M |
| 2009 | $ 369M | $ 19M | $ 229M |
| 2008 | $ 281M | -$ 42M | $ 236M |
| 2007 | $ 210M | $ 19M | $ 290M |
| 2006 | $ 159M | $ 73M | $ 227M |
| 2005 | $ 115M | $ 65M | $ 125M |
| 2004 | $ 73M | $ 15M | $ 82M |
| 2003 | $ 53M | -$ 9M | $ 68M |
| 2002 | $ 30M | -$ 23M | $ 122M |
| 2001 | $ 5M | -$ 37M | $ 56M |
| 2000 | $ 2M | -$ 75M | $ 215M |
| IPO1999 | $ 400K | -$ 33M | $ 51M |
United Therapeutics Corporation fundamental performance
Between 2020 and 2025, revenue grew from $ 1.48B to $ 3.18B and net income grew from $ 514M to $ 1.33B. Revenue increased in 4 of those 5 years; net income in 4.
Across United Therapeutics Corporation's full reported history, from 1999 to 2025, revenue grew from $ 400K to $ 3.18B and net income went from -$ 33M to $ 1.33B. Revenue increased in 89% of the years measured; net income in 70%.
United Therapeutics Corporation currently holds a 20-year HDB Score of 7.6 out of 10. How the HDB Score is calculated.
Membership
Continue UTHR’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
